SCHEMBL225013

SCHEMBL225013

[C]1C(c2ccccc2)=Cc2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677598 0.71 PTPN1 (0.40) ALDH1A1
SCHEMBL5085740 0.67 TSHR (0.35)
SCHEMBL1336762 0.67 KDM4E (0.30) ALDH1A1
SCHEMBL709852 0.64 MAPT (0.39) ALDH1A1
Biphenyl SCHEMBL3387747 0.61 ALDH1A1 (0.90) ALDH1A1
Biphenyl SCHEMBL10585997 0.61 ALDH1A1 (0.90) ALDH1A1
SCHEMBL205284 0.58
Biphenyl SCHEMBL28991329 0.58 ALDH1A1 (0.82) ALDH1A1
Biphenyl SCHEMBL945675 0.58 ALDH1A1 (0.82) ALDH1A1
Biphenyl SCHEMBL6546569 0.58 ALDH1A1 (0.82) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196267-B1 NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS APEIRON SYNTHESIS SA (PL) 2023-11-29 EP claimed
EP-3256505-B1 CYCLIC OLEFIN RESIN COMPOSITIONS COMPRISING FUNCTIONAL ELASTOMERS MATERIA INC (US) 2023-11-29 EP claimed
US-20230322830-A1 Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis APEIRON SYNTHESIS S.A. (PL) 2023-10-12 US claimed
EP-4196267-A1 NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS Apeiron Synthesis S.A. (PL) 2023-06-21 EP claimed
WO-2022038121-A1 NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS APEIRON SYNTHESIS S.A. (PL) 2022-02-24 WO claimed
US-20210403654-A1 ADHESION PROMOTER COMPOSITIONS FOR CYCLIC OLEFIN RESIN COMPOSITIONS MATERIA, INC. (US) 2021-12-30 US claimed
EP-3353187-B1 METAL CARBENE OLEFIN METATHESIS CATALYSTS UMICORE AG & CO KG (DE) 2021-07-21 EP claimed
US-11066434-B2 Metal complexes comprising aniline type ligands UMICORE AG & CO. KG 2021-07-20 US claimed
US-20210155648-A1 OLEFIN METATHESIS CATALYSTS UMICORE AG & CO KG (DE) 2021-05-27 US claimed
US-10907018-B2 Adhesion promoter compositions for cyclic olefin resin compositions MATERIA, INC. (US) 2021-02-02 US claimed
EP-1757613-B1 Multicoordinated metal complexes for use in metathesis reactions TELENE SAS (FR) 2011-01-19 EP claimed
US-7687635-B2 Metal complexes useful in metathesis and other reactions TELENE S.A.S. (FR) 2010-03-30 US claimed
EP-1115491-B1 CATALYST COMPLEX WITH PHENYLINDENYLIDENE LIGAND UNIV NEW ORLEANS FOUNDATION (US) 2009-08-05 EP claimed
JP-2009504401-A 2009-02-05 JP claimed
US-20080293905-A9 MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS RIMTEC CORPORATION (JP) 2008-11-27 US claimed
WO-2007022945-A2 MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS VIACATT N.V. (BE) 2007-03-01 WO claimed
EP-1757613-A1 Multicoordinated metal complexes for use in metathesis reactions Viacatt N.V. (BE) 2007-02-28 EP claimed
US-20070043188-A1 MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS TELENE S.A.S. (FR) 2007-02-22 US claimed
EP-1577282-A2 Metal complexes for use in olefin methathesis and atom or group transfer reactions Universiteit Gent (BE) 2005-09-21 EP claimed
WO-2005082819-A2 METAL COMPLEXES FOR USE IN OLEFIN METATHESIS AND ATOM GROUP TRANSFER REACTIONS UNIVERSITEIT GENT (BE) 2005-09-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322830-A1 Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis CYP4F11, CYP4F3, CYP4F12 ALDH1A1 1063/4885
US-11066434-B2 Metal complexes comprising aniline type ligands SQLE, SOAT1, SOAT2 ALDH1A1 1330/4885
US-20210155648-A1 OLEFIN METATHESIS CATALYSTS MOGAT2, SQLE, FDFT1 ALDH1A1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.